801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.China
Home ProductsSmall Volume Parenteral

Antimalarial Drug Small Volume Parenteral Quinine Dihydrochloride Injection

Antimalarial Drug Small Volume Parenteral Quinine Dihydrochloride Injection

    • Antimalarial Drug Small Volume Parenteral Quinine Dihydrochloride Injection
  • Antimalarial Drug Small Volume Parenteral Quinine Dihydrochloride Injection

    Product Details:

    Place of Origin: China
    Brand Name: Newlystar
    Certification: GMP
    Model Number: 200mg/2ml; 400mg/4ml; 600mg/2ml

    Payment & Shipping Terms:

    Minimum Order Quantity: 300, 000 amps
    Price: Negotiation
    Packaging Details: 10 x 10amps/box
    Delivery Time: 45days
    Payment Terms: L/C, T/T
    Supply Ability: one million amps per day
    Contact Now
    Detailed Product Description
    Product: Quinine Dihydrochloride Injection Specification: 200mg/2ml; 400mg/4ml; 600mg/2ml
    Standard: BP, USP Packing: 10 X 10amps/box
    High Light:

    small volume injection


    lyophilized injection

    Antimalarial Drug Small Volume Parenteral Quinine Dihydrochloride Injection



    Product : Quinine Dihydrochloride Injection

    Specification : 200mg/2ml; 400mg/4ml; 600mg/2ml

    Standard : BP, USP

    Packing : 10 x 10amps/box


    Description :

    An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It was used commonly and as a bitter and flavoring agent, and is still useful for the treatment of babesiosis. Quinine is also useful in some muscular disorders, especially nocturnal leg cramps and myotonia congenita, because of its direct effects on muscle membrane and sodium channels. The mechanisms of its antimalarial effects are not well understood.



    For the treatment of malaria and leg cramps


    Structured Indications:

    Malaria caused by Plasmodium falciparum



    Quinine is used parenterally to treat life-threatening infections caused by chloroquine-resistant Plasmodium falciparum malaria. Quinine acts as a blood schizonticide although it also has gametocytocidal activity against P. vivax and P. malariae. Because it is a weak base, it is concentrated in the food vacuoles of P. falciparum. It is thought to act by inhibiting heme polymerase, thereby allowing accumulation of its cytotoxic substrate, heme. As a schizonticidal drug, it is less effective and more toxic than chloroquine. However, it has a special place in the management of severe falciparum malaria in areas with known resistance to chloroquine.


    Mechanism of action

    The theorized mechanism of action for quinine and related anti-malarial drugs is that these drugs are toxic to the malaria parasite. Specifically, the drugs interfere with the parasite's ability to break down and digest hemoglobin. Consequently, the parasite starves and/or builds up toxic levels of partially degraded hemoglobin in itself.



    G6PD deficiency, history of quinineinduced blackwater fever or thrombocytopenic purpura, hypersensitivity to quinine or its components, optic neuritis, pregnancy, tinnitus




    acetazolamide, sodium bicarbonate: Increased risk of quinine toxicity

    aluminum-containing antacids: Possibly delayed or decreased quinine absorption

    aminophylline, theophylline: Possibly increased quinine adverse effects

    antimyasthenics: Possibly antagonized antimyasthenic effect on skeletal muscle

    atorvastatin: Increased blood atorvastatin level; increased risk of myopathy or


    carbamazepine, phenobarbital, phenytoin: Possibly increased blood level of these

    drugs; possibly decreased blood quinine level

    cimetidine: Possibly reduced quinine clearance

    class 1A antiarrhythmics such as disopyramide, procainamide, quinidine and class III antiarrhythmics such as amiodarone, dofetilide, sotalo; CYP3A4 substrates such as astemizole, cisapride,halofantrine, pimozide, quinidine, terfenadine; macrolide antibiotics such as erythromycin; mefloquine: Increased risk of QT prolongation and life-threatening


    debrisoquine, desipramine, dextromethorphan, flecainide, metoprolol, paroxetine: Possibly increased blood levels of these drugs; increased risk of adverse reactions digoxin: Increased blood digoxin level

    erythromycin, ketoconazole, ritonavir, troleandomycin: Possibly increased blood quinine level

    flecainide, quinidine: Increased risk of prolongation of QRS interval

    hemolytics, neurotoxic drugs, ototoxic drugs: Increased risk of toxicity of these drugs

    hepatic enzyme inducers, rifampin: Possibly decreased blood quinine level

    mefloquine: Increased risk of seizures

    neuromuscular blockers: Potentiated

    neuromuscular blockade oral anticoagulants: Possibly increased anticoagulant effects and risk of bleeding

    verapamil: Increased risk of prolonged PR interval


    Adverse Reactions

    CNS: Dizziness, headache

    CV: Prolonged PR, QRS or QT intervals;

    torsades de pointes; ventricular arrhythmias

    EENT: Blurred vision, hearing loss,

    tinnitus, vision changes including blindness

    ENDO: Hypoglycemia

    GI: Abdominal or epigastric pain, diarrhea,

    nausea, vomiting

    HEME: Thrombocytopenia

    SKIN: Diaphoresis, flushing

    Contact Details
    Newlystar (Ningbo) Medtech Co.,Ltd.

    Contact Person: Luke Liu

    Send your inquiry directly to us (0 / 3000)

    Other Products